Inovio Pharmaceuticals, Inc. — Q2 2011 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2011. Unaudited interim financial statements. Inovio develops DNA vaccines and electroporation delivery technology; all potential human products remained in research and development, with no product sales.
Financial results and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $2.42 million; prior year $1.13 million | $5.53 million; prior year $2.51 million |
| Research and development expense | $4.46 million; prior year $3.08 million | $8.89 million; prior year $5.81 million |
| General and administrative expense | $3.09 million; prior year $3.03 million | $6.41 million; prior year $6.08 million |
| Operating loss | $5.14 million; prior year $4.98 million | $9.52 million; prior year $9.38 million |
| Net loss attributable to Inovio | $2.82 million, or $0.02 per share; prior year $7.62 million, or $0.07 per share | $5.23 million, or $0.04 per share; prior year $9.91 million, or $0.10 per share |
| Cash used in operating activities | Not provided for the quarter | $9.96 million; prior year $7.81 million |
Revenue growth was driven primarily by higher grant and government contract revenue, particularly from NIAID. R&D spending increased, including costs for the HPV Phase II study and NIAID-funded work. Q2 net loss was lower despite a higher operating loss, chiefly because other income included a $4.9 million gain from revaluing warrant liabilities; this was a noncash fair-value item. For the six months, other income was $7.22 million, while the loss from the affiliate investment was $2.98 million.
At June 30, cash and cash equivalents were $30.59 million and short-term certificates of deposit were $5.76 million. Working capital was $28.7 million, versus $16.4 million at December 31, 2010. Total liabilities were $12.28 million; the filing reports no outstanding line-of-credit balance. The company raised approximately $23.0 million net in a January stock-and-warrant offering and a further $1.4 million net under its ATM program during the first half. Common shares outstanding were about 127.3 million at June 30, up from 105.0 million at year-end.
Material changes and notable items
- Total revenue more than doubled year over year for both the quarter and first half, largely reflecting higher grant revenue. License and milestone revenue remained comparatively small.
- First-half operating cash use increased year over year as research, clinical, and engineering spending rose. The January financing drove the increase in cash and working capital.
- Warrant liabilities increased to $4.87 million from $0.37 million at year-end, after issuance of warrants in the January financing and subsequent fair-value remeasurement. The remeasurement materially affected reported earnings.
- OncoSec asset-sale consideration included $250,000 received and another $2.75 million scheduled over two years, plus potential royalties. No receivable was recorded for the scheduled payments because collection was not considered reasonably assured. The transaction involved disclosed prior business and board relationships.
- The company reported an accumulated deficit of $200.1 million and stated it had operated at a loss since 1994. It expected continued losses and reliance on external financing, potentially beyond Q3 2013; it cautioned that additional financing may not be available on acceptable terms.
Outlook, risks, and controls
No specific financial forecast or earnings guidance was provided. Management expected substantial ongoing R&D and operating losses, no product-sale revenue for at least several years, and continued need for outside capital; the company might never achieve positive cash flow or profitability. The NIAID contract had a stated five-year value of $24.6 million, with two one-year options that could bring total potential value to $26.9 million; future funding and option exercise were not assured.
Principal risks include clinical and regulatory failure or delay, manufacturing and trial execution, dependence on grants and a limited number of partners, competition, intellectual-property disputes, and the need for additional capital and potential shareholder dilution. The filing said risk factors had not materially changed from the 2010 Form 10-K. Management reported disclosure controls were effective as of June 30, 2011 and no material change in internal control over financial reporting. No legal proceedings were reported.
Key facts for investors to verify
- Cash runway and financing needs against the reported $9.96 million first-half operating cash use and management’s expectation of continued external funding.
- How much of the improved net loss reflects noncash warrant remeasurement rather than operating performance; review warrant valuation assumptions and potential dilution.
- Progress, costs, and results of the HPV Phase II study and other clinical programs, along with the status and funding of NIAID and other grant agreements.
- Collection and timing of the $2.75 million scheduled OncoSec payments, and any potential royalties or related-party considerations.
- Subsequent events, including the July 2011 VGX Int’l share purchase and reported ownership percentage of approximately 16.1%.